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Abstract 
Insulin autoimmune syndrome (IAS) is a rare cause of spontaneous hypoglycemia in which insulin-
antibody complexes circulate in abundance. The pathophysiology and optimal treatment remain 
unclear. Here we describe a case with novel adverse cardiovascular features where B-cell depletion 
with rituximab led to resolution of dysglycemia and this vascular phenotype.  
History & Examination 
A 37 year-old female presented to the emergency department having collapsed; venous glucose 
measured 50mg/dL. She reported recurrent dizziness since the birth of her fifth child 10 months 
previously and had . During several of these she recorded low capillary blood glucose (36-
52mg/dL) when symptomatic. Her past history included gestational diabetes during the most recent 
pregnancy, treated with insulin aspart (NovoRapid
®
), insulin glargine (Lantus
®
) and metformin. 
These therapies had been discontinued 1 month post-partum.  
Investigation 
Blood count and renal, liver, thyroid and adrenal function were all normal. HbA1c was 41mmol/mol 
(5.9%). A cContinuous glucose monitoring system (CGMS) demonstrated early-morning 
(asymptomatic) hypoglycemia and post-prandial hyperglycemia. During hypoglycemia she had high 
circulating insulin (39,181pmol/L; C-peptide 1,046pmol/L). Insulin assay was performed as 
previously described.(1) Only 4% of total immunoreactive insulin was recovered from plasma 
supernatant following polyethylene glycol precipitation, consistent with the presence of high 
molecular-weight insulin immunoreactivity. Insulin eluted from a gel filtration column 
predominantly in high molecular-weight fractions (Figure); exogenous insulin exchange was 
employed to refute heterophilic antibody assay interference and confirm the presence of insulin-
antibody complexes (‘macroinsulin’).(1) Serum anti-insulin IgG concentration was 171mg/L (0-5).  
We diagnosed insulin autoimmune syndrome (IAS), a term commonly used in patients without 
previous exposure to exogenous insulin. Here, we cannot exclude that the insulin antibodies 
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generated were in response to exogenous insulin, but severe hypoglycemia did not develop until 
many months after cessation of insulin therapy. Moreover, aAntibodies developing following after 
exposure to exogenous insulin rarely bind insulin with sufficient capacity or affinity to perturb 
glycemia.(2) Here, we cannot exclude that the insulin antibodies generated were in response to 
exogenous insulin, but severe hypoglycemia did not develop until many months after insulin 
therapy stopped and the post-partum presentation is typical for recrudescence, or first appearance, 
of autoimmune disease.  
The patient was fitted with a CGMS with hypoglycemia alarm and prescribed a diet comprising of 
frequent low glycemic-index carbohydrate meals. As sSignificant hypoglycemia continued. Thus, 
prednisone was commenced at (1mg/kg/day) and titrated according to CBG readings and symptoms 
to 10mg/day over three months. To reduce anti-insulin antibodies, we gave the anti-CD20 
monoclonal antibody rituximab was administered.  
A rRepeat CGM after six weeks revealed intermittent hypoglycemia and sustained daytime 
hyperglycemia. Over months, there were reductions in total insulin, anti-insulin antibody 
concentration and antibody-bound insulin (Figure). These were associated with reduced 
hypoglycemia and iimprovedmprovement in hypoglycemic awareness. By 6 months, hypoglycemia 
was rare and post-prandial hyperglycemia had improved (CGM peak glucose on CGMS 
162.0mg/dL). There were no adverse events and prednisone was discontinued after 10 months, 
following after which no further hypoglycemia was recorded.  
Recurrent hypoglycemia (in type I diabetes mellitus) is associated with endothelial dysfunction, 
inflammation and increased cardiovascular risk.(3) In other contexts, rituximab has been shown to 
improve measures of endothelial function.(4) Thus, we explored the cardiovascular phenotype 
associated with IAS, before and after treatment. Carotid-femoral pulse wave velocity (PWV) was 
7.6m/s at presentation and 5.2m/s at 6 months (5.2-8.0m/s); there was no change in blood pressure 
over this period. This suggests elevated arterial stiffness at presentation , and is associated with 
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cardiovascular risk.(4) Other surrogate markers of endothelial dysfunction Plasma ADMA (an 
endogenous inhibitor of nitric oxide biosynthesis), endothelin-1 (a potent vasoconstrictor) and urate 
(associated with arterial stiffness and cardiovascular risk) were all higher at disease presentation 
than at 6 months (Figure). Circulating levels of miR-126 rose following treatment (Figure). This 
microRNA is endothelial-enriched and is considered thought to maintain endothelial homeostasis 
and promote vasculogenesis.(4) There was minimal change in control miR-122-5p. 
Conclusions 
Treatment of IAS is poorly defined. Historically, glucocorticoids and plasmapharesis were used for 
refractory cases. We show that B-cell depletion with rituximab induces a sustained reduction in 
anti-insulin antibodies, circulating insulin and the frequency of hypoglycemia. Rituximab has been 
used successfully in two other cases of IAS.(5,6) However in one, concomitant use of 
plasmapheresis, methotrexate and intravenous immunoglobulin make it difficult to ascribe the 
beneficial therapeutic effect solely to rituximab.  
Our report is novel in providing We also present data to suggesting an adverse vascular phenotype 
in IAS that is reversible when dysglycemia resolves. We speculate that recurrent 
hypoglycemiadysglycemia , hyperglycemia and circulating immune complexes may contribute to 
vascular dysfunction in IAS, but further study is required to determine the underlying mechanism, 
and how treatment improves vascular health.  
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Figure: (A) Reportable insulin concentration, total insulin estimation & free insulin estimation against time. Day 
0 is the day of first presentation; prednisone was commenced on day 44; rituximab was administered on days 44 and 58. 
Insulin concentrations shown here were measured using the DiaSorin LIAISON® assay; an alternative assay (Abbot 
Architect®) gave consistent results. Follow-up insulin determination was undertaken on neat plasma (‘measured 
insulin’) and after 1:49 dilution in 0.9% saline to promote insulin-antibody dissociation and reduce negative assay 
interference by antibodies (‘total insulin’) as well as in supernatant following polyethylene glycol precipitation (‘free’ 
insulin). ○ represents measured insulin concentration >3000pmol/L in neat plasma. (B) Serum anti-insulin IgG 
concentration (in-house ImmunoCAP® assay; reference range 0-5). (C) Changes in plasma macroinsulin in 
response to immunosuppressive therapy. At presentation, only 4% of total immunoreactive insulin was recovered 
from plasma supernatant following polyethylene glycol precipitation, consistent with the presence of high molecular-
weight insulin immunoreactivity. Predominantly high molecular-weight insulin consistent with macroinsulin was 
demonstrable using gel filtration chromatography at presentation. The eElution volumes of immunoglobulin and (Ig), 
albumin (alb) and monomeric insulin (ins) are shown by the black and white arrows respectively; the majority of insulin 
co-eluted with immunoglobulins. Follow-up investigations on day 271 confirmed a decrease in macroinsulin. (D) 
Changes in circulating markers of endothelial / vascular function at presentation (‘pre’) and at 6 months (‘post’). 
ADMA, asymmetric dimethylarginine; ET-1, endothelin-1.  
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History & Examination 
A 37 year-old female presented to the emergency department having collapsed; venous glucose 
measured 50mg/dL. She reported recurrent dizziness since the birth of her fifth child 10 months 
previously and had recorded low capillary blood glucose (36-52mg/dL) when symptomatic. Her 
past history included gestational diabetes during the most recent pregnancy, treated with insulin 
aspart, insulin glargine and metformin. These therapies had been discontinued 1 month post-partum.  
Investigation 
Blood count and renal, liver, thyroid and adrenal function were all normal. HbA1c was 41mmol/mol 
(5.9%). Continuous glucose monitoring (CGM) demonstrated early-morning (asymptomatic) 
hypoglycemia and post-prandial hyperglycemia. During hypoglycemia she had high circulating 
insulin (39,181pmol/L; C-peptide 1,046pmol/L). Insulin assay was performed as previously 
described.(1) Insulin eluted from a gel filtration column in high molecular-weight fractions 
(Figure). Serum anti-insulin IgG concentration was 171mg/L (0-5).  
We diagnosed insulin autoimmune syndrome (IAS), a term commonly used in patients without 
previous exposure to exogenous insulin. Here, we cannot exclude that the insulin antibodies 
generated were in response to exogenous insulin, but severe hypoglycemia did not develop until 
many months after cessation of insulin therapy. Moreover, antibodies developing after exposure to 
exogenous insulin rarely bind insulin with sufficient capacity or affinity to perturb glycemia.(2)  
The patient was fitted with CGM with hypoglycemia alarm and prescribed a diet of frequent low 
glycemic-index carbohydrate meals. As significant hypoglycemia continued, prednisone was 
commenced (1mg/kg/day) and titrated according to CBG readings to 10mg/day over three months. 
To reduce anti-insulin antibodies, we gave the anti-CD20 monoclonal antibody rituximab.  
Repeat CGM after six weeks revealed intermittent hypoglycemia and sustained daytime 
hyperglycemia. Over months, there were reductions in total insulin, anti-insulin antibody 
concentration and antibody-bound insulin (Figure). These were associated with reduced 
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hypoglycemia and improved hypoglycemic awareness. By 6 months, hypoglycemia was rare and 
post-prandial hyperglycemia had improved (CGM peak glucose 162.0mg/dL). There were no 
adverse events and prednisone was discontinued after 10 months, after which no further 
hypoglycemia was recorded.  
Recurrent hypoglycemia is associated with endothelial dysfunction, inflammation and increased 
cardiovascular risk.(3) Thus, we explored the cardiovascular phenotype associated with IAS, before 
and after treatment. Carotid-femoral pulse wave velocity (PWV) was 7.6m/s at presentation and 
5.2m/s at 6 months (5.2-8.0m/s); there was no change in blood pressure over this period. This 
suggests elevated arterial stiffness at presentation, associated with cardiovascular risk. Other 
surrogate markers of endothelial dysfunction were all higher at disease presentation than at 6 
months (Figure). Circulating miR-126 rose following treatment (Figure). This microRNA is 
endothelial-enriched and is thought to maintain endothelial homeostasis and promote 
vasculogenesis.(4) There was minimal change in control miR-122-5p. 
Conclusions 
Treatment of IAS is poorly defined. Historically, glucocorticoids and plasmapharesis were used for 
refractory cases. We show that B-cell depletion with rituximab induces a sustained reduction in 
anti-insulin antibodies, circulating insulin and the frequency of hypoglycemia. Rituximab has been 
used successfully in two other cases of IAS.(5,6) However in one, concomitant use of 
plasmapheresis, methotrexate and intravenous immunoglobulin make it difficult to ascribe the 
beneficial therapeutic effect to rituximab.  
Our report is novel in providing data to suggest an adverse vascular phenotype in IAS that is 
reversible when dysglycemia resolves. We speculate that recurrent dysglycemia may contribute to 
vascular dysfunction in IAS, but further study is required to determine the underlying mechanism.  
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Figure: (A) Reportable insulin concentration, total insulin estimation & free insulin estimation against time. Day 
0 is the day of first presentation; prednisone was commenced on day 44; rituximab was administered on days 44 and 58. 
Insulin concentrations shown here were measured using the DiaSorin LIAISON® assay; an alternative assay (Abbot 
Architect®) gave consistent results. Follow-up insulin determination was undertaken on neat plasma (‘measured 
insulin’) and after 1:49 dilution in 0.9% saline to promote insulin-antibody dissociation and reduce negative assay 
interference by antibodies (‘total insulin’) as well as in supernatant following polyethylene glycol precipitation (‘free’ 
insulin). ○ represents measured insulin concentration >3000pmol/L in neat plasma. (B) Serum anti-insulin IgG 
concentration (in-house ImmunoCAP® assay; reference range 0-5). (C) Changes in plasma macroinsulin in 
response to immunosuppressive therapy. At presentation, only 4% of total immunoreactive insulin was recovered 
from plasma supernatant following polyethylene glycol precipitation, consistent with the presence of high molecular-
weight insulin immunoreactivity. Predominantly high molecular-weight insulin consistent with macroinsulin was 
demonstrable using gel filtration chromatography at presentation. The elution volumes of immunoglobulin and 
monomeric insulin are shown by the black and white arrows respectively; the majority of insulin co-eluted with 
immunoglobulins. Follow-up investigations on day 271 confirmed a decrease in macroinsulin. (D) Changes in 
circulating markers of endothelial / vascular function at presentation (‘pre’) and at 6 months (‘post’). ADMA, 
asymmetric dimethylarginine; ET-1, endothelin-1.  
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